The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study
- PMID: 15816106
- DOI: 10.1016/j.radonc.2004.12.018
The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study
Abstract
Background and purpose: Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck (HNSCC), but the response is heterogeneous. EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy. The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced.
Patients and methods: Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy. EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data.
Results: Tumors with high EGFr (84%) responded better to moderately accelerated radiotherapy, than carcinomas with low EGFr, using locoregional control as endpoint and a similar pattern was seen, stratifying by well/moderate vs. poor tumor differentiation. Therefore, a combined parameter was constructed showing a more prominent separation of response: tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control, HR 0.54 (0.37-0.78), whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation, HR 0.8 (0.51-1.25). These results reflected the disease specific survival as well and were confirmed in multivariable analyses.
Conclusions: Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation.
Similar articles
-
Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.J Clin Oncol. 2005 Aug 20;23(24):5560-7. doi: 10.1200/JCO.2005.06.411. J Clin Oncol. 2005. PMID: 16110017 Clinical Trial.
-
The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck.Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):561-6. doi: 10.1016/j.ijrobp.2003.09.043. Int J Radiat Oncol Biol Phys. 2004. PMID: 14751528
-
Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial.Eur J Cancer. 2013 Oct;49(15):3202-9. doi: 10.1016/j.ejca.2013.06.024. Epub 2013 Jul 15. Eur J Cancer. 2013. PMID: 23867129 Clinical Trial.
-
Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma.Radiat Oncol. 2012 Aug 24;7:143. doi: 10.1186/1748-717X-7-143. Radiat Oncol. 2012. PMID: 22920680 Free PMC article. Review.
-
Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Pathol Res Pract. 2011. PMID: 21531084 Review.
Cited by
-
Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.Int J Oncol. 2016 Dec;49(6):2285-2293. doi: 10.3892/ijo.2016.3721. Epub 2016 Oct 5. Int J Oncol. 2016. PMID: 27748899 Free PMC article.
-
Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer.World J Gastroenterol. 2014 Feb 28;20(8):2005-13. doi: 10.3748/wjg.v20.i8.2005. World J Gastroenterol. 2014. PMID: 24587675 Free PMC article. Review.
-
Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.Int J Colorectal Dis. 2012 Oct;27(10):1325-32. doi: 10.1007/s00384-012-1446-2. Epub 2012 Mar 20. Int J Colorectal Dis. 2012. PMID: 22430888 Clinical Trial.
-
Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.Cancer Sci. 2014 Jul;105(7):818-24. doi: 10.1111/cas.12421. Epub 2014 May 16. Cancer Sci. 2014. PMID: 24730770 Free PMC article.
-
Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.Int J Colorectal Dis. 2015 Mar;30(3):337-45. doi: 10.1007/s00384-014-2097-2. Epub 2015 Jan 8. Int J Colorectal Dis. 2015. PMID: 25564344 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous